Schizophrenia Sensory Gating Deficit With Quetiapine - Full Text View

Sponsors and Collaborators:	New Mexico VA Healthcare System AstraZeneca
Information provided by:	New Mexico VA Healthcare System
ClinicalTrials.gov Identifier:	NCT00536783

Purpose

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.

Condition	Intervention
Schizophrenia	Drug: Quetiapine

MedlinePlus related topics: Schizophrenia

Drug Information available for: Quetiapine Quetiapine fumarate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Schizophrenia Sensory Gating Deficit With Quetiapine

Further study details as provided by New Mexico VA Healthcare System:

Estimated Enrollment:	20
Study Start Date:	April 2004
Study Completion Date:	March 2006

Detailed Description:

.Problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. Examination of this requires neuoimaging techniques with high temporal resolution. High-density EEG and MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory gating. In a number of recent studies patient treated with novel antipsychotics have been shown to have P50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. To date, there is no literature on the effects of quetiapine on sensory gating. Subjects who meet all inclusion criteria and have been on a stable dose of quetiapine for three months will receive a clinical interview, an MRI, MEG, and neuropsychological testing to determine if patients with schizophrenia who are treated with quetiapine will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating.

Eligibility

Ages Eligible for Study:	18 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patient Population

Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for DSM-IV
No comorbid diagnosis of PTSD
responders to quetiapine, determined by continuous treatment at the same dose of quetiapine and absence of psychiatric hospitalization for at least 3 months
No history of drug dependency in their lifetime
No history of alcohol or other substance abuse in the 6 months prior to entry into the study
No history of head injury with loss of consciousness for more than 5 minutes
No history of seizure disorder
No mood stabilizing agents
Between 18-65 and
Able to sign informed consent

Normal Controls

Matched in age and gender to patient population
No history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the SCID
No history of alcohol or other substance abuse in the previous 6 months
No family history of psychotic disorder in first degree relatives as assessed by the FH-RDC diagnostic interview
No history of head injury with loss of consciousness for more than 5 minutes
No history of seizure disorder
Between 18-65
Able to sign informed consent

Exclusion Criteria:

Subjects will be excluded from participating in this study if they:

Require treatment with a mood stabilizer
Have had an inpatient hospitalization in the past 3 months
Have a history of a neurological disorder
Have any other axis I diagnosis besides schizophrenia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00536783

Locations

United States, New Mexico
New Mexico VA Healthcare System
Albuquerque, New Mexico, United States, 87108

Sponsors and Collaborators

New Mexico VA Healthcare System

AstraZeneca

Investigators

Principal Investigator:

Jose M Canive, MD

New Mexico VA Heathcare System / BRINM

More Information

The New Mexico VA Healthcare System website This link exits the ClinicalTrials.gov site

The website for the University of New Mexico Human Research Review Committee which oversees the protection of human subjects for this project. This link exits the ClinicalTrials.gov site

The website for the Biomedical Research Institute of New Mexico which helps administers the funds for this project. This link exits the ClinicalTrials.gov site

Study ID Numbers:	0072, . IRUSQUET0332
Study First Received:	September 27, 2007
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00536783
Health Authority:	United States: Federal Government

Keywords provided by New Mexico VA Healthcare System:

Psychiatry
Antipsychotic
Psychopharmacology
Clinical Trial
Open Label

Schizophrenia
Sensory Gating
Attention
Memory

Study placed in the following topic categories:

Schizophrenia
Quetiapine
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Tranquilizing Agents
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs

Central Nervous System Depressants
Antipsychotic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009